Which neurotransmitter is most commonly targeted to reduce symptoms in clients diagnosed with obsessive-compulsive disorder (OCD)?

Choice A reason: Acetylcholine is primarily involved in peripheral parasympathetic nervous system function and central cognitive processes like memory and attention. While it plays a role in various neuropsychiatric conditions, it is not the primary neurotransmitter system targeted in the standard pharmacological management of obsessive-compulsive disorder symptoms. Choice B reason: Dopamine dysregulation is heavily implicated in schizophrenia and certain tic disorders. While dopamine antagonists are sometimes used as augmenting agents in treatment-resistant OCD, they are not the first-line target. The pathophysiology of OCD is more directly linked to the serotonergic pathways within the orbitofrontal-striatal-thalamic circuitry. Choice C reason: Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter and is the main target for benzodiazepines in treating acute anxiety or panic. However, GABAergic modulation does not address the core intrusive thoughts or ritualistic compulsions of OCD as effectively as medications that increase synaptic serotonin availability. Choice D reason: Serotonin is the primary target because Selective Serotonin Reuptake Inhibitors (SSRIs) are the first-line treatment for OCD. Increasing serotonin levels in the synaptic cleft helps modulate the overactive communication between the orbitofrontal cortex and the basal ganglia, which is thought to drive the repetitive thoughts and behaviors seen in the disorder.